824 related articles for article (PubMed ID: 18550105)
1. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K
J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105
[TBL] [Abstract][Full Text] [Related]
2. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
3. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma.
Johnson TV; Abbasi A; Owen-Smith A; Young A; Ogan K; Pattaras J; Nieh P; Marshall FF; Master VA
J Urol; 2010 Feb; 183(2):480-5. PubMed ID: 20006861
[TBL] [Abstract][Full Text] [Related]
4. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
6. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
7. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Jonasch E; Merchant MM; Spiess PE; Wood CG
Urology; 2007 May; 69(5):835-8. PubMed ID: 17482917
[TBL] [Abstract][Full Text] [Related]
9. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma.
Komai Y; Saito K; Sakai K; Morimoto S
BJU Int; 2007 Jan; 99(1):77-80. PubMed ID: 16956357
[TBL] [Abstract][Full Text] [Related]
10. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
Yoo C; Song C; Hong JH; Kim CS; Ahn H
J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
[TBL] [Abstract][Full Text] [Related]
12. Editorial comment.
Campbell SC; Lane BR
J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
[No Abstract] [Full Text] [Related]
13. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma.
Alamdari FI; Rasmuson T; Grankvist K; Ljungberg B
Scand J Urol Nephrol; 2007; 41(1):5-9. PubMed ID: 17366095
[TBL] [Abstract][Full Text] [Related]
14. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
[TBL] [Abstract][Full Text] [Related]
15. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma.
Ito K; Yoshii H; Sato A; Kuroda K; Asakuma J; Horiguchi A; Sumitomo M; Asano T
J Urol; 2011 Aug; 186(2):430-5. PubMed ID: 21679988
[TBL] [Abstract][Full Text] [Related]
16. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Yokoi S; Deguchi T; Hirose Y
Urology; 2007 May; 69(5):843-8. PubMed ID: 17482919
[TBL] [Abstract][Full Text] [Related]
18. Functional and oncological outcomes of partial nephrectomy of solitary kidneys.
La Rochelle J; Shuch B; Riggs S; Liang LJ; Saadat A; Kabbinavar F; Pantuck A; Belldegrun A
J Urol; 2009 May; 181(5):2037-42; discussion 2043. PubMed ID: 19298974
[TBL] [Abstract][Full Text] [Related]
19. Editorial comment on: Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Novara G
Eur Urol; 2009 May; 55(5):1153-4. PubMed ID: 18930580
[No Abstract] [Full Text] [Related]
20. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
